Rice Hall James & Associates LLC lowered its position in shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) by 3.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,314,943 shares of the biotechnology company’s stock after selling 49,936 shares during the quarter. Rice Hall James & Associates LLC owned approximately 1.87% of Progenics Pharmaceuticals worth $9,678,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Piedmont Investment Advisors LLC acquired a new stake in Progenics Pharmaceuticals during the second quarter worth approximately $103,000. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Progenics Pharmaceuticals during the second quarter worth approximately $108,000. Municipal Employees Retirement System of Michigan boosted its position in Progenics Pharmaceuticals by 4.0% during the second quarter. Municipal Employees Retirement System of Michigan now owns 16,600 shares of the biotechnology company’s stock worth $113,000 after acquiring an additional 640 shares during the last quarter. LS Investment Advisors LLC boosted its position in Progenics Pharmaceuticals by 473.8% during the second quarter. LS Investment Advisors LLC now owns 16,897 shares of the biotechnology company’s stock worth $115,000 after acquiring an additional 13,952 shares during the last quarter. Finally, Aperio Group LLC acquired a new stake in Progenics Pharmaceuticals during the third quarter worth approximately $118,000. Hedge funds and other institutional investors own 90.06% of the company’s stock.

WARNING: “Rice Hall James & Associates LLC Has $9.68 Million Position in Progenics Pharmaceuticals Inc. (PGNX)” was reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.watchlistnews.com/rice-hall-james-associates-llc-has-9-68-million-position-in-progenics-pharmaceuticals-inc-pgnx/1675674.html.

PGNX has been the topic of a number of analyst reports. BidaskClub lowered shares of Progenics Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 11th. Cantor Fitzgerald initiated coverage on shares of Progenics Pharmaceuticals in a research report on Wednesday, July 12th. They set an “overweight” rating and a $15.00 target price on the stock. ValuEngine lowered shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, August 3rd. Aegis restated a “buy” rating and set a $14.00 target price on shares of Progenics Pharmaceuticals in a research report on Tuesday, August 22nd. Finally, Needham & Company LLC reaffirmed a “strong-buy” rating and set a $14.00 price target on shares of Progenics Pharmaceuticals in a research note on Friday, September 1st. Three research analysts have rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. Progenics Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $13.20.

Progenics Pharmaceuticals (NASDAQ:PGNX) last posted its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.21) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.03. The company had revenue of $2.70 million during the quarter, compared to the consensus estimate of $3.58 million. Progenics Pharmaceuticals had a negative net margin of 6.13% and a negative return on equity of 4.11%. The company’s revenue for the quarter was down 95.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.52 earnings per share.

Progenics Pharmaceuticals Company Profile

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.

Want to see what other hedge funds are holding PGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progenics Pharmaceuticals Inc. (NASDAQ:PGNX).

Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.